Andexxa Recall Lawsuit Investigation

Andexxa lawsuits are being investigated following findings that the drug failed to effectively reverse life-threatening bleeding events, while increasing the risk of serious and sometimes fatal clotting complications. These concerns ultimately led the FDA to recall Andexxa and remove it from the U.S. market in December 2025.

Andexxa (coagulation factor Xa recombinant, inactivated-zhzo) received accelerated approval from the FDA in 2018 as an emergency reversal agent for patients taking factor Xa inhibitor blood thinners, such as Xarelto (rivaroxaban) and Eliquis (apixaban). The drug was intended for use in hospital and critical care settings when rapid reversal of anticoagulation was believed necessary to control severe or uncontrolled bleeding.

Although Andexxa was introduced with a boxed warning acknowledging the risk of thrombosis, it was expected to provide a meaningful clinical benefit by reducing bleeding-related harm. However, postmarketing data and required follow-up studies later raised concerns that the drug exposed patients to significant thrombotic risk without delivering the expected benefit as a reversal agent.

After reviewing these findings, the FDA determined that Andexxa’s overall risk–benefit profile no longer justified continued use. In December 2025, regulators issued a safety communication announcing n Andexxa recall, and AstraZeneca confirmed it would withdraw Andexxa from the U.S. market and end all commercial sales by December 22, 2025.

Lawsuit investigations are now focused on whether Andexxa should never have been introduced or kept on the market, given evidence that it did not effectively reverse bleeding events while increasing the risk of serious injuries, including stroke, heart attack, dangerous blood clots, and death.

Who May Qualify for an Andexxa Lawsuit?

Individuals may qualify for financial compensation through an Andexxa lawsuit if they received the reversal agent and later experienced a serious blood clot or clot-related complication, including:

• Stroke
• Heart attack
• Pulmonary embolism
• Deep vein thrombosis (DVT)
• Other dangerous blood clots requiring emergency treatment
• Sudden or unexpected clotting shortly after Andexxa was administered
• Death caused by a blood clot or clot-related complication

If you or a family member suffered one of these injuries after receiving Andexxa, you may be eligible to have your case reviewed as part of an ongoing lawsuit investigation.

2026 Andexxa Lawsuit Investigation Updates

• December 18, 2025 Update: The FDA issued a safety communication stating that postmarketing safety data and clinical trial evidence show an increased risk of serious thrombotic events, including fatal outcomes, in patients treated with Andexxa. Based on these findings, regulators concluded that the risks of the drug outweigh its benefits, prompting AstraZeneca to voluntarily request withdrawal of the biologics license application and confirm that U.S. commercial sales of Andexxa will end by December 22, 2025.
• November 21, 2024 Update: The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee convened to discuss results from the ANNEXA-I trial and the supplemental biologics licensing application submitted by AstraZeneca for Andexxa. During the meeting, committee members reviewed safety and efficacy data as part of the regulatory process to evaluate whether the drug’s clinical benefit was confirmed, a key step preceding later safety actions.

What Is Andexxa?

Andexxa is an intravenous medication used in emergency situations to reverse the effects of certain prescription blood thinners. The drug is administered through an IV infusion by medical professionals in hospital settings when a patient is experiencing life-threatening or uncontrolled bleeding.

The medication was developed for patients taking factor Xa inhibitor anticoagulants, such as rivaroxaban (Xarelto) or apixaban (Eliquis). These blood thinners are commonly prescribed to prevent strokes and blood clots, but they can also carry a risk of severe bleeding. Andexxa was intended to rapidly counteract those blood-thinning effects in emergency situations.

Andexxa works by binding to factor Xa inhibitors in the bloodstream, temporarily blocking their anticoagulant activity. It is typically given as a one-time treatment, sometimes followed by a short continuous infusion, depending on the clinical situation. Use of the drug was generally limited to emergency rooms, trauma centers, and intensive care units, where doctors were responding to events such as intracranial hemorrhage, internal bleeding, or major trauma.

Study Questions Andexxa’s Effectiveness

However, after just a few short years of being on the market, independent research began raising serious questions about whether Andexxa actually saved lives during major bleeding emergencies.

A 2021 study published in the Journal of the American College of Cardiology reviewed data from 60 studies involving more than 4,700 patients who suffered severe bleeding while taking newer blood thinners such as Xarelto and Eliquis. Many of those patients were treated with reversal agents like Andexxa, yet the risk of death from bleeding remained high.

Key findings from the study included:

• Nearly 18 percent of patients died following major bleeding events despite receiving a reversal agent
• More than 20 percent mortality among patients who suffered intracranial, or brain, bleeding
• Effective bleeding control was achieved in only about 78 percent of cases
• Failure to stop bleeding was strongly linked to fatal outcomes
• Researchers also identified a high rate of thromboembolic events associated with Andexxa

The study concluded that while reversal agents were intended to prevent patients from bleeding to death, they often failed to deliver that benefit, while exposing patients to additional clotting risks. These findings added to growing concerns that Andexxa did not meaningfully improve outcomes in life-threatening bleeding situations, even years before the FDA ultimately recalled the drug.

Andexxa Recall Over Thrombotic Events​

On December 18, 2025, the FDA announced an Andexxa recall after concluding that postmarketing safety data and clinical trial evidence showed the drug significantly increased the risk of serious and fatal blood clots. Regulators determined that these risks outweighed any benefit provided by the medication, leading to its withdrawal from the U.S. market in December 2025.

According to the FDA, safety concerns escalated after review of data from the ANNEXA-I trial, which was required as a condition of Andexxa’s accelerated approval. That study showed that individuals treated with Andexxa faced substantially higher and earlier clotting risks compared to patients who received usual care.

Andexxa Blood Clot Risks

• More than double the rate of blood clots: Thrombotic events occurred in 14.6 percent of Andexxa patients, compared to 6.9 percent of patients receiving usual care.
• Higher number of fatal clotting events: Six Andexxa patients died from clot-related complications within 30 days, compared to two deaths in the usual care group.
• Earlier onset of dangerous clots: Of the Andexxa patients who suffered a thrombotic event, 53 percent experienced the event earlier, compared to just 6.3 percent of patients in the usual care group.

The FDA stated that this pattern of increased and earlier clotting events was especially concerning given that Andexxa was administered to critically ill patients in emergency settings.

Andexxa Removed From Market

Based on the overall safety data, regulators concluded that Andexxa posed unacceptable thromboembolic risks and issued a safety communication announcing the recall.

AstraZeneca subsequently confirmed it would withdraw Andexxa from the U.S. market and end all U.S. commercial sales by December 22, 2025, as the FDA continues working to keep healthcare providers and the public informed.

Andexxa Side Effect Lawsuits

Andexxa side effect lawsuits are being investigated after postmarketing studies and FDA safety reviews linked the drug to an increased risk of serious thrombotic events.

What Is a Thromboembolic Event?

A thromboembolic event occurs when a blood clot forms and blocks normal blood flow in a vein or artery. When this happens, oxygen delivery to vital organs can be suddenly reduced or cut off, leading to severe and sometimes fatal complications.

Depending on where the clot occurs or travels, a thromboembolic event can affect the brain, heart, lungs, or other critical organs. These events can develop rapidly and often require immediate medical intervention, which is why the FDA treats them as serious safety concerns.

Andexxa Side Effects Under Review

Based on the FDA’s recall and safety findings, lawsuit investigations are focused on the following thrombotic injuries:

• Blood clots (thrombosis): Lawsuits are being reviewed for patients who developed abnormal or dangerous blood clots after receiving Andexxa. FDA-reviewed data showed that Andexxa individuals experienced more than double the rate of thrombotic events compared to those receiving usual care, raising concerns that the drug increased clotting risk rather than preventing harm.

• Stroke: Andexxa stroke lawsuits are being investigated for those who suffered ischemic strokes linked to clot formation after treatment. Clots blocking blood flow to the brain can cause permanent neurological injury, paralysis, or death and were among the serious thrombotic outcomes cited by regulators.

• Heart attack: Lawsuits involving heart attacks are being evaluated for individuals who experienced clot-related blockages in coronary arteries after receiving Andexxa. These events can result in irreversible heart damage or sudden cardiac death and fall within the thrombotic risk profile identified by the FDA.

• Thrombosis-related death: Wrongful death lawsuits are being investigated for families whose loved ones died from clot-related complications after receiving Andexxa. The FDA reported a higher rate of deaths linked to thrombotic events in Andexxa-treated patients than in those receiving usual care, with fatalities occurring within 30 days of treatment.

Symptoms of Serious Blood Clots After Andexxa

Individuals who experienced thrombotic events after receiving Andexxa often showed sudden and severe symptoms that required immediate medical attention. Symptoms reported in cases involving serious blood clots may include:

• Sudden weakness or numbness, especially on one side of the body
• Difficulty speaking, confusion, or sudden vision changes
• Chest pain or pressure
• Shortness of breath or rapid breathing
• Sudden collapse or loss of consciousness
• Severe headache with no known cause

These symptoms may signal a life-threatening clot affecting the brain, heart, lungs, or other vital organs. The FDA has warned that thrombotic events linked to Andexxa can occur shortly after treatment, requiring immediate medical evaluation.

Andexxa Lawsuit Allegations

Lawsuit investigations into Andexxa focus on whether the drug was unreasonably dangerous and should never have been introduced or kept on the market, given evidence that it failed to effectively reverse bleeding while exposing patients to serious thrombotic risks.

Attorneys reviewing these cases indicate that potential litigation will center on the following allegations:

• Defective and ineffective design, in that Andexxa did not provide meaningful clinical benefit as a bleeding reversal agent while increasing the risk of dangerous clotting events.
• Marketing a reversal agent without confirmed patient benefit, relying on limited approval standards and surrogate measures rather than evidence that the drug improved survival or bleeding outcomes.
• Continuing to sell Andexxa despite mounting evidence of harm, even as postmarketing data and required studies raised concerns that the drug increased thrombotic events without offsetting benefit.
• Exposing critically ill patients to unnecessary risk, by administering a drug that increased the likelihood of serious clotting complications in emergency settings where patients were already medically vulnerable.
• Delaying market withdrawal, despite accumulating evidence that Andexxa’s overall risk–benefit profile was unfavorable and did not justify continued use.
• Keeping the drug available after regulators questioned its clinical value, ultimately leading to an FDA determination that Andexxa posed unacceptable thromboembolic dangers.

These allegations are being examined to determine whether patients and families may have viable product liability and wrongful death claims related to injuries and deaths linked to Andexxa.

Potential Andexxa Lawsuit Compensation

If Andexxa is found to have contributed to serious injury or death, affected patients and families may be eligible to pursue financial compensation through a product liability lawsuit. Future Andexxa recall settlements in these cases may provide financial compensation intended to address the medical, financial, and personal impact of severe clotting injuries linked to the drug.

Potential damages being evaluated in Andexxa lawsuit investigations may include:

• Emergency and hospital care: Costs related to emergency treatment, hospitalization, intensive care, and follow-up medical services required after a thrombotic event.
• Long-term medical complications: Ongoing treatment, rehabilitation, medications, and monitoring for patients who suffered permanent injury from blood clots, stroke, or heart damage.
• Lost income and disability: Wages lost during recovery, reduced earning capacity, or long-term disability caused by clot-related injuries that limit the ability to work.
• Wrongful death damages: Compensation for surviving family members in cases where a loved one died from thrombosis-related complications after receiving Andexxa, including funeral costs and loss of financial support.

Contact an Andexxa Lawyer

Attorneys are currently investigating potential Andexxa lawsuits following the FDA’s recall and market withdrawal of the drug. If you or a loved one received Andexxa and later experienced serious complications or died, you may be eligible to pursue a lawsuit.

Lawyers are offering free consultations, and all cases are handled on a contingency fee basis, which means there are no upfront costs and no legal fees unless compensation is recovered through a settlement or verdict.